Crossmark

Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy

Crossref DOI link: https://doi.org/10.1038/leu.2017.321

Published Online: 2017-11-03

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patel, V K

Lamothe, B

Ayres, M L

Gay, J

Cheung, J P

Balakrishnan, K

Ivan, C https://orcid.org/0000-0002-4848-0168
Morse, J

Nelson, M

Keating, M J

Wierda, W G

Marszalek, J R

Gandhi, V
License Information

Text and Data Mining valid from 2017-11-03
More Information

Article History

Received: 30 July 2017

Revised: 9 October 2017

Accepted: 12 October 2017

First Online: 3 November 2017

Competing interests

: VG and WGW received research and clinical trial funding from Acerta. JPC is an employee of Acerta. The other authors declare no conflict of interest.